EP3250568A1 - Procédé perfectionné pour la préparation de linézolide - Google Patents
Procédé perfectionné pour la préparation de linézolideInfo
- Publication number
- EP3250568A1 EP3250568A1 EP16876979.2A EP16876979A EP3250568A1 EP 3250568 A1 EP3250568 A1 EP 3250568A1 EP 16876979 A EP16876979 A EP 16876979A EP 3250568 A1 EP3250568 A1 EP 3250568A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- compound
- preparation
- isoindole
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 title claims abstract description 34
- 229960003907 linezolid Drugs 0.000 title claims abstract description 32
- GZPUHNGIERMRFC-ZETCQYMHSA-N 4-[[(2s)-oxiran-2-yl]methyl]isoindole-1,3-dione Chemical compound O=C1NC(=O)C2=C1C=CC=C2C[C@H]1CO1 GZPUHNGIERMRFC-ZETCQYMHSA-N 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 29
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 28
- -1 carbamate compound Chemical class 0.000 claims description 23
- 239000002904 solvent Substances 0.000 claims description 21
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 18
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 18
- 150000004681 metal hydrides Chemical class 0.000 claims description 12
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 12
- 229910001516 alkali metal iodide Inorganic materials 0.000 claims description 11
- 229910052987 metal hydride Inorganic materials 0.000 claims description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 9
- 150000007530 organic bases Chemical class 0.000 claims description 8
- 229910052783 alkali metal Inorganic materials 0.000 claims description 7
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 claims description 7
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims description 7
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 claims description 6
- 239000012312 sodium hydride Substances 0.000 claims description 6
- 150000001298 alcohols Chemical group 0.000 claims description 5
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 4
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 4
- 150000004703 alkoxides Chemical class 0.000 claims description 4
- 150000003973 alkyl amines Chemical group 0.000 claims description 4
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 150000002170 ethers Chemical class 0.000 claims description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 235000009518 sodium iodide Nutrition 0.000 claims description 4
- KBRVYEPWGIQEOF-SSDOTTSWSA-N 2-[(2s)-3-chloro-2-hydroxypropyl]isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(C[C@@H](CCl)O)C(=O)C2=C1 KBRVYEPWGIQEOF-SSDOTTSWSA-N 0.000 claims description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 3
- 239000012346 acetyl chloride Substances 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 229930195733 hydrocarbon Natural products 0.000 claims description 3
- 150000002430 hydrocarbons Chemical class 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 claims description 2
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 claims description 2
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 claims description 2
- 229910000103 lithium hydride Inorganic materials 0.000 claims description 2
- RSHAOIXHUHAZPM-UHFFFAOYSA-N magnesium hydride Chemical compound [MgH2] RSHAOIXHUHAZPM-UHFFFAOYSA-N 0.000 claims description 2
- 229910012375 magnesium hydride Inorganic materials 0.000 claims description 2
- 150000003335 secondary amines Chemical class 0.000 claims description 2
- 150000003141 primary amines Chemical class 0.000 claims 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims 1
- FKZUTWSVQLXKQE-OAHLLOKOSA-N 2-[[(5s)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]isoindole-1,3-dione Chemical compound FC1=CC(N2C(O[C@@H](CN3C(C4=CC=CC=C4C3=O)=O)C2)=O)=CC=C1N1CCOCC1 FKZUTWSVQLXKQE-OAHLLOKOSA-N 0.000 abstract description 10
- 239000000543 intermediate Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 238000006243 chemical reaction Methods 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 239000002002 slurry Substances 0.000 description 10
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 8
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- BRLQWZUYTZBJKN-GSVOUGTGSA-N (+)-Epichlorohydrin Chemical compound ClC[C@@H]1CO1 BRLQWZUYTZBJKN-GSVOUGTGSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- VXIWZOWWQMRVRF-NSHDSACASA-N (5s)-5-(aminomethyl)-3-(3-fluoro-4-morpholin-4-ylphenyl)-1,3-oxazolidin-2-one Chemical compound O=C1O[C@@H](CN)CN1C(C=C1F)=CC=C1N1CCOCC1 VXIWZOWWQMRVRF-NSHDSACASA-N 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- DUILGEYLVHGSEE-ZETCQYMHSA-N 2-[[(2s)-oxiran-2-yl]methyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C[C@H]1CO1 DUILGEYLVHGSEE-ZETCQYMHSA-N 0.000 description 1
- FKZUTWSVQLXKQE-UHFFFAOYSA-N 2-[[3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]isoindole-1,3-dione Chemical compound FC1=CC(N2C(OC(CN3C(C4=CC=CC=C4C3=O)=O)C2)=O)=CC=C1N1CCOCC1 FKZUTWSVQLXKQE-UHFFFAOYSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- LFJKVEOWXYKQGT-UHFFFAOYSA-N 5,6-diamino-1h-pyrimidine-4-thione Chemical compound NC=1NC=NC(=S)C=1N LFJKVEOWXYKQGT-UHFFFAOYSA-N 0.000 description 1
- FZLSDZZNPXXBBB-KDURUIRLSA-N 5-chloro-N-[3-cyclopropyl-5-[[(3R,5S)-3,5-dimethylpiperazin-1-yl]methyl]phenyl]-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine Chemical compound C[C@H]1CN(Cc2cc(Nc3ncc(Cl)c(n3)-c3c[nH]c4cc(C)ccc34)cc(c2)C2CC2)C[C@@H](C)N1 FZLSDZZNPXXBBB-KDURUIRLSA-N 0.000 description 1
- SJVGFKBLUYAEOK-SFHVURJKSA-N 6-[4-[(3S)-3-(3,5-difluorophenyl)-3,4-dihydropyrazole-2-carbonyl]piperidin-1-yl]pyrimidine-4-carbonitrile Chemical compound FC=1C=C(C=C(C=1)F)[C@@H]1CC=NN1C(=O)C1CCN(CC1)C1=CC(=NC=N1)C#N SJVGFKBLUYAEOK-SFHVURJKSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- PXHGOOPTKALBDO-OGFXRTJISA-N ClC[C@H](CN1C(C=2C(C1=O)=CC=CC2)=O)O.C2(C=1C(C(N2)=O)=CC=CC1)=O Chemical compound ClC[C@H](CN1C(C=2C(C1=O)=CC=CC2)=O)O.C2(C=1C(C(N2)=O)=CC=CC1)=O PXHGOOPTKALBDO-OGFXRTJISA-N 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- YLNSNVGRSIOCEU-ZCFIWIBFSA-N [(2r)-oxiran-2-yl]methyl butanoate Chemical compound CCCC(=O)OC[C@H]1CO1 YLNSNVGRSIOCEU-ZCFIWIBFSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229940113088 dimethylacetamide Drugs 0.000 description 1
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
- 239000003759 ester based solvent Substances 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- VOVZXURTCKPRDQ-CQSZACIVSA-N n-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=NC=C(C(=O)NC=2C=CC(OC(F)(F)Cl)=CC=2)C=C1C1=CC=NN1 VOVZXURTCKPRDQ-CQSZACIVSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229940061740 zyvox Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to an improved process for the preparation of Linezolid. More specifically, the present invention relates to an improved process for preparing(S)-N-[[3-[3-fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl] phthalimide and ( ⁇ -glycidylphthalimide intermediates, which are used in the preparation of Linezolid .
- Linezolid is a synthetic antibiotic, the first of the oxazolidinone class, used for the treatment of infections caused by multi -resistant bacteria including streptococcus and methicillin-resistant Staphylococcus aureus (MRSA).
- MRSA methicillin-resistant Staphylococcus aureus
- the antibacterial effect of oxazolidinones is by working as protein synthesis inhibitors, targeting an early step involving the binding of N-formylmethionyl-t-RNA to the ribosome.
- Linezolid is marketed by Pfizer under the trade names "Zyvox”and it is chemically known as (S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl] methyl] acetamide having the formula (I).
- Linezolid is first disclosed in U.S. Pat. No. 5,688,792 and its process describes by using of R -glycidylbutyrate which results in the formation of (R) - N-[[3-[3-fluoro-4- morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methanol which in the subsequent stages has to be converted to various intermediary compounds to finally form Linezolid.
- the said process also encompasses intermediary azide compound, which is difficult to handle at an industrial level, which is depicted in the scheme-I given below:
- WO 1999/24393 Al discloses a process for the preparation of oxazolidinone derivatives, which is depicted in the scheme-II given below: Roxa- NH-CO-O-X!
- R OXA is phenyl substituted with one fluoro and one substituted amino group, wherein the substituted amino groups include 4-(benzyloxycarbonyl)- 1-piperazinyl, 4- morpholinyl and 4-hydroxyacetylpiperazinyl
- X l is C1-C20 alkyl
- X 2 is CI
- Br RN is C1-C5 alkyl
- WO' 393 does not disclose any specific examples or suitable conditions for the preparation of Linezolid.
- WO 2005/099353 A2 discloses a process for the preparation of Linezolid, which is depicted in the scheme-Ill given below:
- WO 2006/008754 Al discloses a process for the preparation of Linezolid, which is depicted in scheme-IV given below
- Scheme-IV discloses a process for preparing Linezolid by reacting a compound of structure (1) with a compound of structure (2) at a temperature range from ambient temperature to about 65 °C to provide a compound of structure (3), which is hydrolyzed and subsequently acylated to give Linezolid, which is depicted in the scheme-V below:
- US 5,608,110 discloses process for the preparation of 2-[(2,S)-oxiran-2-ylmethyl]-lH- isoindole-l,3(2H)-dione (I) comprising, reaction of phthalimide with (S)-(+)- epichlorohydrin under reflux in nitrogen atmosphere, ethyl acetate/hexane to get (S)-l- chloro-3-phthalimido-2-propanol which is cyclized in presence of NaH/THF.
- US 6,875,875 discloses a process for the preparation of 2-[(2,S)-oxiran-2-ylmethyl]-lH- isoindole-l,3(2H)-dione (I) comprising reaction of phthalimide with (S)- epichlorohydrin in presence of alkali metal carbonate, alkali metal hydrogen carbonate or a quaternary ammonium salt to get (,S)-l-chloro-3-phthalimido-2-propanol which is cyclized in presence of metal alkoxides.
- the main objective of the present invention is to provide cost-effective and commercially feasible process for the preparation of Linezolid.
- Another objective of the present invention is to provide a process for the preparation of (S)-N-[[3-[3-fluoro-4-[4-morpholinyl] phenyl]-2-oxo-5-oxazolidinyl] methyl] phthalimide and (3 ⁇ 4)-glycidyl phthalimide intermediates, which employs less expensive, easily available and eco-friendly reagents.
- R represents hydrogen, C1-C5 alkyl, aryl, aralkyl; with (S)-glycidyl phthalimide of formula (IX)
- R alkyl or aryl
- the organic base is primary or secondary alkyl amines having C1-C5 carbon atoms.
- R represents hydrogen, C1-C5 alkyl, aryl, aralkyl; with (S)-glycidyl phthalimide of formula (IX)
- the reaction is carried using an alkali metal iodides and in the presence or absence of a solvent at a temperature in the range of 60 to 120°C.
- the reaction is carried out for a period of 10 to 14 hours.
- the reaction is carried using a lithium tertiary butoxide used in the range 0.2-0.4 mole equivalents in presence of a suitable solvent at a temperature in the range of 40 to 100°C.
- the reaction is carried out for a period of 4 to 12 hours.
- suitable alkali metal iodides used is selected from lithium iodide, sodium iodide, potassium iodide and the like ;
- Suitable solvent used is selected from alcohols such as methanol, ethanol, isopropyl alcohol, and the like or mixture thereof; ketones, such as methyl isobutyl ketone, methyl ethyl ketone, n-butanone, and the like; halogenated solvents, such as dichloromethane, ethylene dichloride, chloroform, and the like; esters, such as ethyl acetate, n-propyl acetate, isopropyl acetate, and the like; hydrocarbon solvents, such as toluene, xylene, cyclohexane, and the like; ethers, such as 1,4-dioxane, tetrahydrofuran, and the like; and amides such as N,N-
- step b) subjecting the compound of formula(VI) with aqueous methyl amine or hydrazine hydrate, c) acylating the product of step b), and
- the reaction between formula (III) with (S)-Glycidyl phthalimide of formula(IX) is carried out in presence of suitable alkali metal iodides (or) metal hydrides and solvent at suitable temperature to give a compound of formula(VI); further it is subjected to deprotection with hydrazine hydrae (or) aqueous methyl amine to give (S)-5-Aminomethyl-3-(3-fluoro-4-morpholin-4-yl-phenyl)- oxazolidin-2-one, which is subsequently acylated with acetic anhydride or acetyl chloride to give (S)-N-[[3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5- oxazolidinyljmethyl] acetamide (Linezolid) of formula I.
- the reaction between formulas (III) with (S)-Glycidyl phthalimide of formula (IX) is carried out in presence of suitable metal hydrides and solvent at suitable temperature to give a compound of formula (VI); the reaction is completed within a less span of time and provides good quantity of yield with high purity
- the alkali metal iodides is selected from lithium iodide, sodium iodide, potassium iodide and the like; metal hydrides is selected from sodium hydride, lithium hydride or magnesium hydride.
- the suitable solvent used is selected from alcohols such as methanol, ethanol, isopropyl alcohol, and the like or mixture thereof; ketones, such as methyl isobutyl ketone, methyl ethyl ketone, n-butanone, and the like; halogenated solvents, such as dichloromethane, ethylene dichloride, chloroform, and the like; esters, such as ethyl acetate, n-propyl acetate, isopropyl acetate, and the like; hydrocarbon solvents, such as toluene, xylene, cyclohexane, and the like; ethers, such as 1,4-dioxane, tetrahydrofuran, and the like; and amides such as N,N- dimethylformamide, N,N- dimethyl acetamide and the like or dimethyl sulfoxide or mixture of solvents thereof
- the present invention further involves conversion of compound of
- the acylation is carried out in presence of acetic anhydride or acetyl chloride.
- the reaction is performed at or below boiling temperature of the solvent used, more preferably between 10°C and boiling temperature of the solvent used and even more preferably at boiling temperature of the solvent used. Time required for completion of the reaction depends on factors such as solvent used and temperature at which the reaction is carried.
- the present invention relates to an improved process for the preparation of2-[(2,S)-oxiran-2-ylmethyl]-lH-isoindole-l,3(2H)-dione of formula IX comprising the steps of: a) Phthalimide reacted with (,S)-(+)-Epichlorohydrin in presence of organic base in an organic solvent at the temperature of 60° C to obtain (,S)-l-chloro-3- phthalimido-2-propanol.
- the organic base is primary or secondary alkyl amines having C1-C5 carbon atoms.
- the organic base is selected from primary or secondary alkyl amines having Ci- C5 carbon atoms such as methylamine, ethylamine, ethyl methylamine, diethylamine, dipropylamine, dibutylamine, preferably diethylamine.
- the organic solvent is selected from the group comprising of alcohols, ethers, esters, nitriles having C1-C4 carbon atoms. Preferably alcohols.
- the alcohol is selected from methanol, ethanol, propanol, isopropanol, butanol;
- the ether solvents are selected from diethyl ether, tetrahydrofuran etc.;
- the ester solvents are selected from ethyl acetate, methyl acetate, etc.;
- nitriles are selected from acetonitrile, propionitrile, butyronitrile etc.
- (,S)-l-chloro-3-phthalimido-2-propanol is cyclized in presence of alkali metal alkoxides to obtain 2-[(2,S)-oxiran-2-ylmethyl]-lH-isoindole-l,3(2H)-dione
- Cyclization is carried out in presence of alkali metal alkoxides as the procedure described in US 6,875,875.
- Linezolid produced according to the present invention may be in the form of amorphous or crystalline form I and form II.
- the compound of formula (I) or Linezolid having HPLC purity is not less than 99%.
- the present invention is simple, operation friendly and industrial applicable process. 2. The process is commercially viable and results the compounds in high yield, which makes the process cost effective
- the present invention provides high purity compound of formulas (I), (VI) and (IX) with very less impurities profile.
- reaction mixture was cooled to ambient temperature, ethyl acetate (50 ml) was added, and resultant slurry was stir for 30 min at 25-30 ° C & filtered the solid.
- the resultant crude solid was added to ethyl acetate ( 250 ml) at 25-30°C and heated to 70-75°C, stirred for 15-20 min, cooled the slurry to 25-30°C & Stir for 30 min.
- reaction mass was cooled to below 20°C, quenched with 25 ml of methanol to decompose the excess sodium hydride, distilled out solvent and added methanol (125 ml). The resulting slurry was stir for 30 min at 25-30° C and filtered.
- reaction mass was cooled to below 20°C, quenched with 25 ml of methanol to decompose the excess sodium hydride, further added methanol (125 ml) and the resulting slurry was stir for 30 min at 25-30° C and filtered.
- Methyl amine solution (50 g) was added to a mixture of methanol (100 ml), DM water (400 ml) and (5S) 2-[3-(3-Fluoro-4-mo holin-4-yl-phenyl)-2-oxo-oxazolidin-5- ylmethyl]-isoindole-l,3-dione (100 g 0.235 moles ) at 25-30°C.
- the reaction mixture was stirred, slowly raised to 80-85°C and stirred for 2-3 hours at 80-85°C.
- the reaction mixture was allowed to cool at 25-30°C; followed by addition of dichloromethane (500 ml) and stirred for 15 min to separate the layers.
- Purified water 500 ml was added to the MDC layer and mixture was acidified to pH 2.0-3.0 with dilute hydrochloric acid and stirred for 10-15 min and two layers were separated and again basified with aqueous ammonia pH 10.0-11.0. to separate the MDC layer, and it was distilled out by atmospheric pressure completely to get the residual product of (5S)-5-(amino methyl)- 3-[3-fluoro-4-(morpholin-4-yl) phenyl]-l,3-oxazolidin-2-one.
- Dichloromethane 400 ml was added to the residue and acetic anhydride (25 g) was slowly added at 25-30°C over a period of 60 min.
- reaction mixture was stirred for 60 min at 25-30°C.After completion of reaction, 5% aqueous sodium bicarbonate solution was slowly added to reaction mixture, stirred for 15 min and the two layers were separated. The dichloromethane layer was washed with D M Water (200 ml). The dichloromethane layer was filtered through hi-flow and dichl orom ethane was distilled out completely under vacuum below 40°C. Cyclohexane (500 ml) was added to the residue and heated to 45-50°C.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201641013830 | 2016-04-21 | ||
PCT/IB2016/053003 WO2017182853A1 (fr) | 2016-04-21 | 2016-05-23 | Procédé perfectionné pour la préparation de linézolide |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3250568A1 true EP3250568A1 (fr) | 2017-12-06 |
EP3250568A4 EP3250568A4 (fr) | 2018-08-01 |
Family
ID=60115753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16876979.2A Withdrawn EP3250568A4 (fr) | 2016-04-21 | 2016-05-23 | Procédé perfectionné pour la préparation de linézolide |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3250568A4 (fr) |
KR (1) | KR101832115B1 (fr) |
AU (1) | AU2016403208B2 (fr) |
NZ (1) | NZ741891A (fr) |
RU (1) | RU2766082C9 (fr) |
WO (1) | WO2017182853A1 (fr) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024393A1 (fr) | 1997-11-07 | 1999-05-20 | Pharmacia & Upjohn Company | Procede de production d'oxazolidinones |
WO2014141067A2 (fr) | 2013-03-14 | 2014-09-18 | Benova Labs Pvt Limited | Procédé pour la préparation de dérivés d'oxazolidinone |
IN2013CH05865A (fr) | 2013-12-16 | 2015-06-19 | Optimus Drugs P Ltd | |
IN2014CH00444A (fr) | 2014-01-31 | 2015-08-07 | Optimus Drugs P Ltd |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1768967B1 (fr) * | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Nouveaux intermediaires pour linezolide et composes correspondants |
WO2011114210A2 (fr) * | 2010-03-15 | 2011-09-22 | Jubilant Life Sciences Limited | Procédés de préparation de linézolide |
JP5865898B2 (ja) * | 2010-04-30 | 2016-02-17 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | リネゾリドを調製するためのプロセス |
SI2595968T1 (sl) * | 2011-02-24 | 2016-01-29 | Lee Pharma Limited | Novi postopek za pripravo linezolida in njegovih novih intermediatov |
CN103420933B (zh) * | 2012-05-26 | 2016-03-02 | 鲁南制药集团股份有限公司 | 一种利奈唑胺的制备方法 |
-
2016
- 2016-05-23 WO PCT/IB2016/053003 patent/WO2017182853A1/fr active Application Filing
- 2016-05-23 AU AU2016403208A patent/AU2016403208B2/en active Active
- 2016-05-23 RU RU2018109135A patent/RU2766082C9/ru active
- 2016-05-23 NZ NZ741891A patent/NZ741891A/en unknown
- 2016-05-23 KR KR1020177029421A patent/KR101832115B1/ko active IP Right Grant
- 2016-05-23 EP EP16876979.2A patent/EP3250568A4/fr not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024393A1 (fr) | 1997-11-07 | 1999-05-20 | Pharmacia & Upjohn Company | Procede de production d'oxazolidinones |
WO2014141067A2 (fr) | 2013-03-14 | 2014-09-18 | Benova Labs Pvt Limited | Procédé pour la préparation de dérivés d'oxazolidinone |
IN2013CH05865A (fr) | 2013-12-16 | 2015-06-19 | Optimus Drugs P Ltd | |
IN2014CH00444A (fr) | 2014-01-31 | 2015-08-07 | Optimus Drugs P Ltd |
Non-Patent Citations (7)
Title |
---|
"Letters", CHEMICAL & ENGINEERING NEWS, 13 September 1982 (1982-09-13), pages 4, 5, 43, XP055581856 |
ANONYMOUS: "Explosives Incident Report No. 170 - Static Ignition of Sodium Hydride", EXPLOSIVES ACCIDENT/ INCIDENT ABSTRACTS SEPT. 1961 THRU JUNE 1967, October 1967 (1967-10-01), pages 2pp, XP055679866 |
ANONYMOUS: "Letters", CHEMICAL & ENGINEERING NEWS, 13 June 1966 (1966-06-13), pages 6 - 9, XP055581966 |
ANONYMOUS: "Sodium hydride", NEW JERSEY DEPARTMENT OF HEALTH AND SENIOR SERVICES HAZARDOUS SUBSTANCE FACT SHEET, March 1995 (1995-03-01), pages 1 - 6, XP055581846 |
PANDEY BHAWANA, FULEKAR M.H.: "Environmental Management - Strategies for chemical disaster", RESEARCH JOURNAL OF CHEMICAL SCIENCES, vol. 1, no. 1, April 2011 (2011-04-01), pages 111 - 117, XP055581853 |
See also references of WO2017182853A1 |
TREVOR LAIRD: "Special Feature Section: Safety of Chemical Processes- Safety Feature", ORGANIC PROCESS RESEARCH DEVELOPMENT, vol. 9, no. 6, 2005, pages 951, XP055581961 |
Also Published As
Publication number | Publication date |
---|---|
EP3250568A4 (fr) | 2018-08-01 |
NZ741891A (en) | 2020-05-29 |
AU2016403208B2 (en) | 2018-10-25 |
AU2016403208A1 (en) | 2018-05-10 |
KR20170128485A (ko) | 2017-11-22 |
KR101832115B1 (ko) | 2018-02-23 |
RU2766082C9 (ru) | 2022-02-22 |
WO2017182853A1 (fr) | 2017-10-26 |
RU2766082C1 (ru) | 2022-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1768967B1 (fr) | Nouveaux intermediaires pour linezolide et composes correspondants | |
US7351824B2 (en) | Process for the preparation of linezolid and related compounds | |
US6998420B2 (en) | Oxazolidinone compounds | |
US20080091011A1 (en) | Novel crystalline form of linezolid | |
US9376407B2 (en) | Process for preparation of Linezolid and its novel intermediates | |
WO2013046211A1 (fr) | Procédés de préparation du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morpholinyl) phényl]-1,3-oxazolidin-5-yl}méthyl)-2-thiophène-carbomaxide et de ses intermédiaires | |
USRE47606E1 (en) | Process for the preparation of linezolid | |
US9643939B1 (en) | Process for the preparation of linezolid | |
AU2016403208B2 (en) | An improved process for the preparation of Linezolid | |
US9593104B2 (en) | Process for the preparation of oxazolidinone derivatives | |
WO2003093247A2 (fr) | Nouveaux agents antibacteriens | |
US20220267284A1 (en) | Method for synthesizing n-substituted phenyl-5-hydroxymethyl-2-oxazolidinone | |
WO2014045292A1 (fr) | Procédé amélioré pour la préparation d'un intermédiaire de linézolide | |
US9586913B2 (en) | Processes for the preparation of linezolid using novel intermediates | |
WO2014170908A1 (fr) | Procédé de préparation de dérivés oxazolidinone | |
WO2018055499A1 (fr) | Synthèse monotope pour la préparation d'antibactériens de phtalimido oxazolidinone substitués et de composés d'oxazolidinone anti-harombotiques à l'aide d'un catalyseur hétérogène recyclable |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20170629 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: VELIVELA, SRINIVASA RAO Inventor name: RANE, DNYANDEV RAGHO Inventor name: DESI REDDY, SRINIVAS REDDY Inventor name: PEKETI, SUBBA REDDY |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20180702 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 263/00 20060101AFI20180626BHEP Ipc: C07D 263/20 20060101ALI20180626BHEP |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: RANE, DNYANDEV RAGHO Inventor name: VELIVELA, SRINIVASA RAO Inventor name: PEKETI, SUBBA REDDY Inventor name: DESI REDDY, SRINIVAS REDDY |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20190506 |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230629 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20231110 |